The Road Not Taken: Transferability Issues in Multinational Trials
- 27 August 2013
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 31 (10) , 863-876
Abstract
National regulatory agencies often have to use cost-effectiveness (CE) data from multinational randomized controlled trials (RCTs) for national decision making on reimbursement of new drugs. We need to make the best use of these patient-level data to obtain estimates of country-specific CE. Several methods, ranging from simple to statistically complex, have existed for years. We investigated which of these methods are used to estimate CE ratios in economic evaluations performed alongside recent, multinational RCTs that enrolled at least 500 patients.Keywords
This publication has 53 references indexed in Scilit:
- The Analysis of Multinational Cost-Effectiveness Data for Reimbursement DecisionsPharmacoEconomics, 2010
- Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative AnalysisPLOS Medicine, 2010
- An Economic Evaluation of Rosuvastatin Treatment in Systolic Heart Failure: Evidence from the CORONA TrialEuropean Journal of Heart Failure, 2009
- Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical TrialsPharmacoEconomics, 2009
- Utilities of the EQ-5DPharmacoEconomics, 2009
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force ReportValue in Health, 2009
- Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical ModelingMedical Decision Making, 2007
- The Dutch tariff: results and arguments for an effective design for national EQ‐5D valuation studiesHealth Economics, 2006
- Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: Results from the LIPID studyAmerican Heart Journal, 2006
- Design, Analysis and Presentation of Multinational Economic StudiesPharmacoEconomics, 2002